Benchmark lowered the firm’s price target on OmniAb (OABI) to $6 from $8 and keeps a Buy rating on the shares. Financial results for Q4 came in below the firm’s expectations, notes the analyst, who adds that “on the positive side,” OmniAb reported the signing of 10 new license agreements in 2024, including two in Q4.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OABI: